Aprogen Medicines Inc. (007460.KS)
- Previous Close
655.00 - Open
653.00 - Bid 646.00 x --
- Ask 649.00 x --
- Day's Range
646.00 - 664.00 - 52 Week Range
646.00 - 1,794.00 - Volume
989,838 - Avg. Volume
1,739,744 - Market Cap (intraday)
171.896B - Beta (5Y Monthly) 0.39
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 27, 2007
- 1y Target Est
--
Aprogen Medicines Inc. designs, manufactures, and maintains plant facilities for steelwork, petrochemistry, shipbuilding, power plant, and LNG base industries in South Korea. The company also offers thermal and cold spray services; and clad rolls, clad plates, wear plates, clad pipes and fittings, and plasma transferred arcs. In addition, it provides Nukon system, a special heat-preservation system that keeps the pipe facility of the internal equipment of the containment building working safely in the pressurized water reactor power plant; foamglas, a cellular glass insulation product; and fireproof insulation works in the POSCO furnaces and boilers. The company was formerly known as Aprogen KIC Inc. and changed its name to Aprogen Medicines Inc. April 2021. Aprogen Medicines Inc. was founded in 1971 and is based in Seongnam-si, South Korea.
www.aprogen.comRecent News: 007460.KS
View MorePerformance Overview: 007460.KS
Trailing total returns as of 5/20/2025, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 007460.KS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 007460.KS
View MoreValuation Measures
Market Cap
174.29B
Enterprise Value
244.33B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.26
Price/Book (mrq)
1.17
Enterprise Value/Revenue
1.76
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.69%
Return on Assets (ttm)
-9.37%
Return on Equity (ttm)
-23.40%
Revenue (ttm)
150.11B
Net Income Avi to Common (ttm)
-58.08B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
43.66B
Total Debt/Equity (mrq)
25.84%
Levered Free Cash Flow (ttm)
-43.85B